FDA Seeks Standardization For NGS Tumor Testing
This article was originally published in The Gray Sheet
Without some standardization of cancer tumor tissue collection methods, sample enrichment, and synchronized sequencing criteria and platforms, next-generation sequencing tests could be of low quality for diagnoses, researchers cautioned at a recent FDA workshop. The agency is likely to develop a guidance to clarify best methods, an FDA official says.
Register for our free email digests: